GlassScriptPhysician profile
Lorraine Dajani
NPI 1437153707
$5,522.75
in general payments reported to CMS, 2019-2025
33 companies · $22.11 in 2025
The $22.11 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,487 · 2020: $239 · 2021: $1,087 · 2022: $1,770 · 2023: $584 · 2024: $334 · 2025: $22.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,654.73 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $444.58 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $366.50 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $359.14 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $314.83 | 2019-2022 | |
| Mannkind Corporation | $251.95 | 2019-2020 | |
| Radius Health, INC. | $202.90 | 2019-2022 | |
| Horizon Therapeutics Plc | $200.13 | 2019-2022 | |
| Insulet Corporation | $197.33 | 2019-2022 | |
| Amgen INC. | $149.45 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.59 | 2019-2022 | |
| Valeritas, INC. | $133.46 | 2019 | |
| Ibsa Pharma INC. | $124.37 | 2019-2022 | |
| Lilly USA, LLC | $119.82 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $96.36 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $85.53 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $82.44 | 2019 | |
| Shire North American Group INC | $82.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.85 | 2019-2021 | |
| Amryt Pharma Holdings LTD | $52.99 | 2022 | |
| Abbvie INC. | $50.51 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $49.63 | 2019-2020 | |
| Lifescan, INC. | $47.87 | 2021-2022 | |
| Medtronic, INC. | $38.92 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $37.77 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $32.74 | 2021 | |
| Merck Sharp & Dohme LLC | $25.64 | 2019-2021 | |
| Zealand Pharma US, INC. | $23.34 | 2021 | |
| Recordati_rare_diseases_inc. | $20.59 | 2021 | |
| Nevro Corp. | $16.24 | 2022 | |
| Vistapharm, INC. | $15.28 | 2021 | |
| Endo Pharmaceuticals INC. | $13.21 | 2022 | |
| Medtronic Minimed, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Dajani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.